Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy

Am J Hematol. 2022 Jan 1;97(1):E27-E31. doi: 10.1002/ajh.26406. Epub 2021 Nov 23.

Affiliations

¹ Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
² Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.

No abstract available

Publication types

Clinical Trial
Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal / therapeutic use
Antibodies, Neutralizing / immunology*
Antibodies, Viral / immunology
Antineoplastic Agents / therapeutic use
BNT162 Vaccine / therapeutic use*
COVID-19 / complications*
COVID-19 / immunology
COVID-19 / prevention & control
Female
Humans
Immunoglobulin Light-chain Amyloidosis / complications*
Immunoglobulin Light-chain Amyloidosis / drug therapy
Immunoglobulin Light-chain Amyloidosis / immunology
Kinetics
Male
Middle Aged
Prospective Studies
SARS-CoV-2 / immunology*

Substances

Antibodies, Monoclonal
Antibodies, Neutralizing
Antibodies, Viral
Antineoplastic Agents
daratumumab
BNT162 Vaccine